Morgan Stanley raised the firm’s price target on enGene (ENGN) to $19 from $18 and keeps an Overweight rating on the shares after the company provided updated data from the pivotal cohort of its Phase 2 LEGEND trial, investigating its non-viral gene therapy detalimogene in Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer patients. Detalimogene’s profile appears competitive with other NMIBC agents and 6-month CR was the “standout measure,” says the analyst, who sees the update improving detalimogene’s product profile.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene price target raised to $33 from $30 at Oppenheimer
- enGene price target raised to $10 from $4 at UBS
- Cautious Hold Rating for enGene Holdings Amid Competitive Trial Results and Market Uncertainty
- enGene price target raised to $21 from $18 at Citizens JMP
- Here’s Why enGene Holdings Stock Is Soaring Today